| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_266d10289a36543e118c944d6450b51e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1feb35ff97772d97d8756f6127374a44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7210a52c80e1c8fa67c6a034ffa8aa8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10e4b1416c6e66e0ade5429212414964
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_554fe9377321aa5d1113426b89907da9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 |
| filingDate |
2013-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ffdecddc180ca44fdb112fa2ea6b543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af80bd9f80aa29aabd07bb84f9ee8c05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4470f9defaf1f790f0ae4f18818087aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_126da2038c13cf7d62c9e4f0b65a8daa |
| publicationDate |
2014-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2014011750-A8 |
| titleOfInvention |
Laquinimod formulations without alkalizing agent |
| abstract |
The subject invention provides a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler, and an amount of a lubricant, wherein the stable pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent. The subject invention also provides processes for making the stable pharmaceutical composition and sealed packages comprising the stable pharmaceutical composition. The subject invention additionally provides method for treating a subject afflicted with a form of multiple sclerosis or for alleviating a symptom of multiple sclerosis in a subject afflicted with a form of multiple sclerosis comprising administering to the subject a stable pharmaceutical composition as described herein. The subject invention further provides for use of a stable pharmaceutical composition as described herein for treating a subject afflicted with a form of multiple sclerosis or for alleviating a symptom of multiple sclerosis in a subject afflicted with a form of multiple sclerosis. |
| priorityDate |
2012-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |